There are compelling data showing that targeting MCL-1 represents a therapeutic opportunity in breast cancer with model systems revealing that breast cancer may be dependent on MCL-1, and that MCL-1 inhibition can enhance the effect of conventional cancer therapies [9–12, 16–19]. This evidence concerns the gene MCL1 and breast carcinoma.